
Indivior PLC (INDV) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
302.0M
Gross Profit
250.0M
82.78%
Operating Income
71.0M
23.51%
Net Income
18.0M
5.96%
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
1.7B
Shareholders Equity
-286.0M
Cash Flow Metrics
Operating Cash Flow
72.0M
Free Cash Flow
70.0M
Revenue & Profitability Trend
Indivior PLC Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.2B | 1.1B | 901.0M | 791.0M | 647.0M |
Cost of Goods Sold | 231.0M | 186.0M | 159.0M | 127.0M | 97.0M |
Gross Profit | 957.0M | 907.0M | 742.0M | 664.0M | 550.0M |
Gross Margin % | 80.6% | 83.0% | 82.4% | 83.9% | 85.0% |
Operating Expenses | |||||
Research & Development | 107.0M | 106.0M | 72.0M | 52.0M | 40.0M |
Selling, General & Administrative | 618.0M | 811.0M | 763.0M | 431.0M | 649.0M |
Other Operating Expenses | 4.0M | - | - | - | - |
Total Operating Expenses | 729.0M | 917.0M | 835.0M | 483.0M | 689.0M |
Operating Income | 228.0M | -8.0M | -91.0M | 181.0M | -156.0M |
Operating Margin % | 19.2% | -0.7% | -10.1% | 22.9% | -24.1% |
Non-Operating Items | |||||
Interest Income | 23.0M | 43.0M | 18.0M | 1.0M | 7.0M |
Interest Expense | 41.0M | 37.0M | 29.0M | 26.0M | 24.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 14.0M | 1.0M | -95.0M | 190.0M | -173.0M |
Income Tax | 11.0M | -1.0M | -42.0M | -15.0M | -25.0M |
Effective Tax Rate % | 78.6% | -100.0% | 0.0% | -7.9% | 0.0% |
Net Income | 3.0M | 2.0M | -53.0M | 205.0M | -148.0M |
Net Margin % | 0.3% | 0.2% | -5.9% | 25.9% | -22.9% |
Key Metrics | |||||
EBITDA | 280.0M | 62.0M | -51.0M | 206.0M | -123.0M |
EPS (Basic) | $-0.36 | $0.01 | $-0.38 | $1.40 | $-1.00 |
EPS (Diluted) | $-0.36 | $0.01 | $-0.38 | $1.35 | $-1.00 |
Basic Shares Outstanding | 132309000 | 137306000 | 139012000 | 145659800 | 146572600 |
Diluted Shares Outstanding | 132309000 | 137306000 | 139012000 | 145659800 | 146572600 |
Income Statement Trend
Indivior PLC Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 319.0M | 316.0M | 774.0M | 1.1B | 858.0M |
Short-term Investments | 1.0M | 94.0M | 119.0M | - | - |
Accounts Receivable | 254.0M | 254.0M | 220.0M | 202.0M | 179.0M |
Inventory | 178.0M | 142.0M | 114.0M | 95.0M | 93.0M |
Other Current Assets | 53.0M | 434.0M | 13.0M | 14.0M | 33.0M |
Total Current Assets | 839.0M | 1.3B | 1.3B | 1.4B | 1.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 39.0M | 0 | 0 | 0 | 0 |
Goodwill | 9.0M | 242.0M | 70.0M | 82.0M | 62.0M |
Intangible Assets | 5.0M | 232.0M | 70.0M | 82.0M | 62.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 28.0M | 9.0M | 18.0M | 84.0M | 82.0M |
Total Non-Current Assets | 481.0M | 691.0M | 510.0M | 388.0M | 344.0M |
Total Assets | 1.3B | 2.0B | 1.8B | 1.8B | 1.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 63.0M | 39.0M | 33.0M | 26.0M | 20.0M |
Short-term Debt | 28.0M | 12.0M | 11.0M | 11.0M | 12.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 10.0M | 125.0M | 79.0M | 61.0M | 10.0M |
Total Current Liabilities | 939.0M | 1.3B | 1.0B | 804.0M | 599.0M |
Non-Current Liabilities | |||||
Long-term Debt | 347.0M | 270.0M | 266.0M | 275.0M | 273.0M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 16.0M | 367.0M | 428.0M | 474.0M | 526.0M |
Total Non-Current Liabilities | 728.0M | 649.0M | 699.0M | 825.0M | 850.0M |
Total Liabilities | 1.7B | 2.0B | 1.7B | 1.6B | 1.4B |
Equity | |||||
Common Stock | 62.0M | 68.0M | 68.0M | 70.0M | 73.0M |
Retained Earnings | -454.0M | 1.2B | 1.3B | 1.4B | 1.3B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -348.0M | 0 | 51.0M | 203.0M | 82.0M |
Key Metrics | |||||
Total Debt | 375.0M | 282.0M | 277.0M | 286.0M | 285.0M |
Working Capital | -100.0M | -42.0M | 240.0M | 640.0M | 588.0M |
Balance Sheet Composition
Indivior PLC Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 2.0M | -4.0M | -85.0M | 213.0M | -156.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 24.0M | 22.0M | 16.0M | 11.0M | 8.0M |
Working Capital Changes | 346.0M | -469.0M | 26.0M | -12.0M | -45.0M |
Operating Cash Flow | 373.0M | -451.0M | -43.0M | 212.0M | -193.0M |
Investing Activities | |||||
Capital Expenditures | -29.0M | -8.0M | -5.0M | -4.0M | -4.0M |
Acquisitions | 0 | -5.0M | 0 | 0 | - |
Investment Purchases | -17.0M | -45.0M | -245.0M | 0 | - |
Investment Sales | 117.0M | 129.0M | 27.0M | 0 | - |
Investing Cash Flow | 70.0M | -53.0M | -223.0M | -4.0M | -4.0M |
Financing Activities | |||||
Share Repurchases | -173.0M | -33.0M | -90.0M | -101.0M | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 332.0M | 0 | 0 | 250.0M | 0 |
Debt Repayment | -240.0M | -12.0M | -3.0M | -236.0M | -4.0M |
Financing Cash Flow | -102.0M | -41.0M | -91.0M | -86.0M | -3.0M |
Free Cash Flow | 5.0M | -368.0M | -10.0M | 319.0M | -197.0M |
Net Change in Cash | 341.0M | -545.0M | -357.0M | 122.0M | -200.0M |
Cash Flow Trend
Indivior PLC Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.99
Forward P/E
21.94
Price to Sales
2.50
PEG Ratio
21.94
Profitability Ratios
Profit Margin
4.52%
Operating Margin
23.51%
Return on Equity
-0.57%
Return on Assets
13.14%
Financial Health
Current Ratio
0.90
Debt to Equity
-1.42
Beta
0.96
Per Share Data
EPS (TTM)
$0.81
Book Value per Share
$-2.06
Revenue per Share
$9.21
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
indv | 2.9B | 28.99 | - | -0.57% | 4.52% | -1.42 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.4B | 21.51 | 5.46 | 9.38% | 13.81% | 53.41 |
Elanco Animal Health | 8.7B | 19.91 | 1.28 | 6.83% | 9.68% | 62.13 |
Regencell Bioscience | 6.1B | - | 878.57 | -47.77% | 0.00% | 0.01 |
Alkermes plc | 4.8B | 14.04 | 2.95 | 23.94% | 23.15% | 4.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.